Summit Trail Advisors’s Medicines Co MDCO Stock Holding History

Summit Trail Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,146	Closed	-$66K	–	1978
2017 Q4	$66K	Buy	+2,146	New	+$66.1K	0.01%	749

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Summit Trail Advisors's MDCO Position: Q1 2018 in Review

Summit Trail Advisors sold out of Medicines Co (MDCO) in Q1 2018, closing a stake of 2,146 shares — an estimated $66K sold.

Summit Trail Advisors first reported a position in MDCO in Q4 2017 and held it in 1 quarter. The position peaked at $66K in Q4 2017. 190 funds tracked by Wall St. Rank hold MDCO as of Q1 2018.

Summit Trail Advisors reported no remaining Medicines Co position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 2,146 Medicines Co shares in Q1 2018, an estimated $66K.
Summit Trail Advisors first reported a position in Medicines Co in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Medicines Co position peaked at $66K in Q4 2017.
190 funds tracked by Wall St. Rank held Medicines Co as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.